Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression
- Autores
- Guilloux, Jean Philippe; Bassi, Sabrina Cecilia; Ding, Ying; Walsh, Chris; Turecki, Gustavo; Tseng, George; Cyranowski, Jill M.; Sibille, Etienne
- Año de publicación
- 2014
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Major depressive disorder (MDD) in general, and anxious-depression in particular, are characterized by poor rates of remission with first-line treatments, contributing to the chronic illness burden suffered by many patients. Prospective research is needed to identify the biomarkers predicting nonremission prior to treatment initiation. We collected blood samples from a discovery cohort of 34 adult MDD patients with co-occurring anxiety and 33 matched, nondepressed controls at baseline and after 12 weeks (of citalopram plus psychotherapy treatment for the depressed cohort). Samples were processed on gene arrays and group differences in gene expression were investigated. Exploratory analyses suggest that at pretreatment baseline, nonremitting patients differ from controls with gene function and transcription factor analyses potentially related to elevated inflammation and immune activation. In a second phase, we applied an unbiased machine learning prediction model and corrected for model-selection bias. Results show that baseline gene expression predicted nonremission with 79.4% corrected accuracy with a 13-gene model. The same gene-only model predicted nonremission after 8 weeks of citalopram treatment with 76% corrected accuracy in an independent validation cohort of 63 MDD patients treated with citalopram at another institution. Together, these results demonstrate the potential, but also the limitations, of baseline peripheral blood-based gene expression to predict nonremission after citalopram treatment. These results not only support their use in future prediction tools but also suggest that increased accuracy may be obtained with the inclusion of additional predictors (eg, genetics and clinical scales).
Fil: Guilloux, Jean Philippe. Universite Paris Sud; Francia. University of Pittsburgh; Estados Unidos
Fil: Bassi, Sabrina Cecilia. University of Pittsburgh; Estados Unidos. Hospital Italiano. Instituto de Ciencias Básicas y Medicina Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ding, Ying. University of Pittsburgh; Estados Unidos
Fil: Walsh, Chris. University of Pittsburgh; Estados Unidos
Fil: Turecki, Gustavo. Douglas Mental Health Institute; Canadá
Fil: Tseng, George. University of Pittsburgh; Estados Unidos
Fil: Cyranowski, Jill M.. University of Pittsburgh; Estados Unidos
Fil: Sibille, Etienne. University of Pittsburgh; Estados Unidos - Materia
-
Depression
Blood
Gene Expression
Biomarker - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/35959
Ver los metadatos del registro completo
id |
CONICETDig_d9fcead24473c8900a436bf140a96f46 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/35959 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major DepressionGuilloux, Jean PhilippeBassi, Sabrina CeciliaDing, YingWalsh, ChrisTurecki, GustavoTseng, GeorgeCyranowski, Jill M.Sibille, EtienneDepressionBloodGene ExpressionBiomarkerhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Major depressive disorder (MDD) in general, and anxious-depression in particular, are characterized by poor rates of remission with first-line treatments, contributing to the chronic illness burden suffered by many patients. Prospective research is needed to identify the biomarkers predicting nonremission prior to treatment initiation. We collected blood samples from a discovery cohort of 34 adult MDD patients with co-occurring anxiety and 33 matched, nondepressed controls at baseline and after 12 weeks (of citalopram plus psychotherapy treatment for the depressed cohort). Samples were processed on gene arrays and group differences in gene expression were investigated. Exploratory analyses suggest that at pretreatment baseline, nonremitting patients differ from controls with gene function and transcription factor analyses potentially related to elevated inflammation and immune activation. In a second phase, we applied an unbiased machine learning prediction model and corrected for model-selection bias. Results show that baseline gene expression predicted nonremission with 79.4% corrected accuracy with a 13-gene model. The same gene-only model predicted nonremission after 8 weeks of citalopram treatment with 76% corrected accuracy in an independent validation cohort of 63 MDD patients treated with citalopram at another institution. Together, these results demonstrate the potential, but also the limitations, of baseline peripheral blood-based gene expression to predict nonremission after citalopram treatment. These results not only support their use in future prediction tools but also suggest that increased accuracy may be obtained with the inclusion of additional predictors (eg, genetics and clinical scales).Fil: Guilloux, Jean Philippe. Universite Paris Sud; Francia. University of Pittsburgh; Estados UnidosFil: Bassi, Sabrina Cecilia. University of Pittsburgh; Estados Unidos. Hospital Italiano. Instituto de Ciencias Básicas y Medicina Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ding, Ying. University of Pittsburgh; Estados UnidosFil: Walsh, Chris. University of Pittsburgh; Estados UnidosFil: Turecki, Gustavo. Douglas Mental Health Institute; CanadáFil: Tseng, George. University of Pittsburgh; Estados UnidosFil: Cyranowski, Jill M.. University of Pittsburgh; Estados UnidosFil: Sibille, Etienne. University of Pittsburgh; Estados UnidosNature Publishing Group2014-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/35959Guilloux, Jean Philippe; Bassi, Sabrina Cecilia; Ding, Ying; Walsh, Chris; Turecki, Gustavo; et al.; Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression; Nature Publishing Group; Neuropsychopharmacology; 40; 3; 9-2014; 701-7100893-133XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1038/npp.2014.226info:eu-repo/semantics/altIdentifier/url/https://www.nature.com/articles/npp2014226info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:37:34Zoai:ri.conicet.gov.ar:11336/35959instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:37:34.719CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression |
title |
Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression |
spellingShingle |
Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression Guilloux, Jean Philippe Depression Blood Gene Expression Biomarker |
title_short |
Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression |
title_full |
Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression |
title_fullStr |
Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression |
title_full_unstemmed |
Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression |
title_sort |
Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression |
dc.creator.none.fl_str_mv |
Guilloux, Jean Philippe Bassi, Sabrina Cecilia Ding, Ying Walsh, Chris Turecki, Gustavo Tseng, George Cyranowski, Jill M. Sibille, Etienne |
author |
Guilloux, Jean Philippe |
author_facet |
Guilloux, Jean Philippe Bassi, Sabrina Cecilia Ding, Ying Walsh, Chris Turecki, Gustavo Tseng, George Cyranowski, Jill M. Sibille, Etienne |
author_role |
author |
author2 |
Bassi, Sabrina Cecilia Ding, Ying Walsh, Chris Turecki, Gustavo Tseng, George Cyranowski, Jill M. Sibille, Etienne |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
Depression Blood Gene Expression Biomarker |
topic |
Depression Blood Gene Expression Biomarker |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Major depressive disorder (MDD) in general, and anxious-depression in particular, are characterized by poor rates of remission with first-line treatments, contributing to the chronic illness burden suffered by many patients. Prospective research is needed to identify the biomarkers predicting nonremission prior to treatment initiation. We collected blood samples from a discovery cohort of 34 adult MDD patients with co-occurring anxiety and 33 matched, nondepressed controls at baseline and after 12 weeks (of citalopram plus psychotherapy treatment for the depressed cohort). Samples were processed on gene arrays and group differences in gene expression were investigated. Exploratory analyses suggest that at pretreatment baseline, nonremitting patients differ from controls with gene function and transcription factor analyses potentially related to elevated inflammation and immune activation. In a second phase, we applied an unbiased machine learning prediction model and corrected for model-selection bias. Results show that baseline gene expression predicted nonremission with 79.4% corrected accuracy with a 13-gene model. The same gene-only model predicted nonremission after 8 weeks of citalopram treatment with 76% corrected accuracy in an independent validation cohort of 63 MDD patients treated with citalopram at another institution. Together, these results demonstrate the potential, but also the limitations, of baseline peripheral blood-based gene expression to predict nonremission after citalopram treatment. These results not only support their use in future prediction tools but also suggest that increased accuracy may be obtained with the inclusion of additional predictors (eg, genetics and clinical scales). Fil: Guilloux, Jean Philippe. Universite Paris Sud; Francia. University of Pittsburgh; Estados Unidos Fil: Bassi, Sabrina Cecilia. University of Pittsburgh; Estados Unidos. Hospital Italiano. Instituto de Ciencias Básicas y Medicina Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Ding, Ying. University of Pittsburgh; Estados Unidos Fil: Walsh, Chris. University of Pittsburgh; Estados Unidos Fil: Turecki, Gustavo. Douglas Mental Health Institute; Canadá Fil: Tseng, George. University of Pittsburgh; Estados Unidos Fil: Cyranowski, Jill M.. University of Pittsburgh; Estados Unidos Fil: Sibille, Etienne. University of Pittsburgh; Estados Unidos |
description |
Major depressive disorder (MDD) in general, and anxious-depression in particular, are characterized by poor rates of remission with first-line treatments, contributing to the chronic illness burden suffered by many patients. Prospective research is needed to identify the biomarkers predicting nonremission prior to treatment initiation. We collected blood samples from a discovery cohort of 34 adult MDD patients with co-occurring anxiety and 33 matched, nondepressed controls at baseline and after 12 weeks (of citalopram plus psychotherapy treatment for the depressed cohort). Samples were processed on gene arrays and group differences in gene expression were investigated. Exploratory analyses suggest that at pretreatment baseline, nonremitting patients differ from controls with gene function and transcription factor analyses potentially related to elevated inflammation and immune activation. In a second phase, we applied an unbiased machine learning prediction model and corrected for model-selection bias. Results show that baseline gene expression predicted nonremission with 79.4% corrected accuracy with a 13-gene model. The same gene-only model predicted nonremission after 8 weeks of citalopram treatment with 76% corrected accuracy in an independent validation cohort of 63 MDD patients treated with citalopram at another institution. Together, these results demonstrate the potential, but also the limitations, of baseline peripheral blood-based gene expression to predict nonremission after citalopram treatment. These results not only support their use in future prediction tools but also suggest that increased accuracy may be obtained with the inclusion of additional predictors (eg, genetics and clinical scales). |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/35959 Guilloux, Jean Philippe; Bassi, Sabrina Cecilia; Ding, Ying; Walsh, Chris; Turecki, Gustavo; et al.; Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression; Nature Publishing Group; Neuropsychopharmacology; 40; 3; 9-2014; 701-710 0893-133X CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/35959 |
identifier_str_mv |
Guilloux, Jean Philippe; Bassi, Sabrina Cecilia; Ding, Ying; Walsh, Chris; Turecki, Gustavo; et al.; Testing the Predictive Value of Peripheral Gene Expression for Nonremission Following Citalopram Treatment for Major Depression; Nature Publishing Group; Neuropsychopharmacology; 40; 3; 9-2014; 701-710 0893-133X CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1038/npp.2014.226 info:eu-repo/semantics/altIdentifier/url/https://www.nature.com/articles/npp2014226 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Nature Publishing Group |
publisher.none.fl_str_mv |
Nature Publishing Group |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613184395149312 |
score |
13.070432 |